Michael Barbella, Managing Editor06.03.22
InVivo Therapeutics Holdings Corp.'s INSPIRE 2.0 Study has reached full enrollment.
The company's 20-patient trial is a randomized, controlled trial featuring 10 acute spinal cord injury subjects in each study arm. It is designed to enhance existing clinical evidence for the Neuro-Spinal Scaffold from InVivo Therapeutics's INSPIRE 1.0 study.
“Reaching full enrollment in our INSPIRE 2.0 study is a significant advancement in our research and development efforts towards a potential treatment for spinal cord injury,” said Richard Toselli, M.D., InVivo's President and CEO. “We're grateful to the study participants, as well as the clinicians, investigators, and staff who have worked relentlessly to make this possible, and of course to our team at InVivo. We're very excited to be continuing towards our goal of serving this patient population and expect to present topline data from the study in Q1 of 2023.”
Details about the INSPIRE 2.0 Study can be found here.
“Completing patient enrollment in the INSPIRE 2.0 Study is a major milestone for the spinal cord injury community, and I am pleased to have had the opportunity to help improve potential treatment options for this underserved patient population,” said Kee Kim, M.D., professor and chief of Spinal Neurosurgery at UC Davis, Sacramento, Calif., and a principal investigator in the INSPIRE 2.0 Study.
InVivo Therapeutics Holdings Corp. is a research and clinical-stage biomaterials and biotechnology company with a focus spinal cord injury treatment. The company was founded in 2005 with proprietary technology co-invented by Robert Langer, Sc.D., professor at Massachusetts Institute of Technology, and Joseph P. Vacanti, M.D., who then was at Boston Children's Hospital and who now is affiliated with Massachusetts General Hospital. The publicly traded company is headquartered in Cambridge, Mass.
The company's 20-patient trial is a randomized, controlled trial featuring 10 acute spinal cord injury subjects in each study arm. It is designed to enhance existing clinical evidence for the Neuro-Spinal Scaffold from InVivo Therapeutics's INSPIRE 1.0 study.
“Reaching full enrollment in our INSPIRE 2.0 study is a significant advancement in our research and development efforts towards a potential treatment for spinal cord injury,” said Richard Toselli, M.D., InVivo's President and CEO. “We're grateful to the study participants, as well as the clinicians, investigators, and staff who have worked relentlessly to make this possible, and of course to our team at InVivo. We're very excited to be continuing towards our goal of serving this patient population and expect to present topline data from the study in Q1 of 2023.”
Details about the INSPIRE 2.0 Study can be found here.
“Completing patient enrollment in the INSPIRE 2.0 Study is a major milestone for the spinal cord injury community, and I am pleased to have had the opportunity to help improve potential treatment options for this underserved patient population,” said Kee Kim, M.D., professor and chief of Spinal Neurosurgery at UC Davis, Sacramento, Calif., and a principal investigator in the INSPIRE 2.0 Study.
InVivo Therapeutics Holdings Corp. is a research and clinical-stage biomaterials and biotechnology company with a focus spinal cord injury treatment. The company was founded in 2005 with proprietary technology co-invented by Robert Langer, Sc.D., professor at Massachusetts Institute of Technology, and Joseph P. Vacanti, M.D., who then was at Boston Children's Hospital and who now is affiliated with Massachusetts General Hospital. The publicly traded company is headquartered in Cambridge, Mass.